GLP-2 (Glucagonlike Peptide-2) and Blood Flow

Regional Blood Flow Clinical Trial

Official title:

The Role of GLP-2 in Univercal Changes in Blood Flow in Humans

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00540215
• Other study ID #: H-D-2007-0050
• Status: Completed
• Phase: N/A
• First received: October 4, 2007
• Last updated: February 10, 2011
• Start date: October 2007
• Est. completion date: February 2008

Study information

• Verified date: October 2007
• Source: Glostrup University Hospital, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: The Regional Committee on Biomedical Research Ethics
• Study type: Interventional

Clinical Trial Summary

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put.

GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure.

The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Description:

se the above

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: February 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• Age 20-60

• Healthy

• No medication

• Not pregnant

Exclusion Criteria:

• All of the persons not meeting the abowe mentioned criteria

Study Design

Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Regional Blood Flow

Intervention

Other:
• Glucagonlike peptide
450 nmol native form, synthetic

Locations

Country	Name	City	State
Denmark	Glostrup University Hospital	Glostrup	Region Hovedstaden

Sponsors (1)

Lead Sponsor	Collaborator
Glostrup University Hospital, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	effect of glp-2		during study
Secondary	potential new ideas for further studies		months to years